Its loss of expression has been shown to favorKrasG12D-dependent precancerous pancreatic lesions [9], inducecell-autonomous myeloproliferative disorders in mice [10] and potentiateTIF1α-induced murine hepatocellular carcinoma [11], thereby supporting aprotective role of TIF1γ in cancer. This evidence concerns the gene TRIM33 and cancer.